Sodium Bicarbonate INJ 8.4%, 50 mEq/50mL (84mg/mL) (1mEq/mL), 50mL Sterile SDV, Rx only, Premier ...
FDA Drug Recall #D-1426-2019 — Class II — June 18, 2019
Recall Summary
| Recall Number | D-1426-2019 |
| Classification | Class II — Moderate risk |
| Date Initiated | June 18, 2019 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Premier Pharmacy Labs Inc |
| Location | Weeki Wachee, FL |
| Product Type | Drugs |
| Quantity | 13150 vials |
Product Description
Sodium Bicarbonate INJ 8.4%, 50 mEq/50mL (84mg/mL) (1mEq/mL), 50mL Sterile SDV, Rx only, Premier Pharmacy Labs, 8265 Commercial Way, Weeki Wachee, FL 34613, NDC: 69623-232-39, barcode 8 69623 23239 3.
Reason for Recall
Lack of Assurance of Sterility: FDA inspection found insufficient environmental controls, potential cross contamination and lack of product specific process validations that can result in a lack of sterility assurance.
Distribution Pattern
Nationwide in the USA
Lot / Code Information
All lots remaining within expiry.
Other Recalls from Premier Pharmacy Labs Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-1421-2019 | Class II | Naloxone HCL Preserved INJ, 500mg/50mL (10mg/mL... | Jun 18, 2019 |
| D-1415-2019 | Class II | Droperidol Injectable Sterile Solution, 0.625mg... | Jun 18, 2019 |
| D-1428-2019 | Class II | SUCCINYLcholine Chloride, 200mg/10mL (20mg/mL),... | Jun 18, 2019 |
| D-1412-2019 | Class II | Brilliant Blue Ophthalmic PF INJ, 0.5mg/mL (0.0... | Jun 18, 2019 |
| D-1422-2019 | Class II | Neostigmine Methylsulfate, 5mg/5mL (1mg/mL), 5m... | Jun 18, 2019 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.